This is the second part of our interview with the esteemed Professor Harvey Risch from Yale University. The interview, which covers a range of aspects of the COVID-19 pandemic, took place on October 20, and the first part was put online on October 24.
Professor Risch, since May, has been an advocate of the early outpatient treatment of COVID-19 for high risk people, and he considers that his position has been reinforced with several studies that came out since. For him, the number one priority in the US and elsewhere is to aggressively use early outpatient therapies for high risk patients.
The interview covers several aspects such as the reliability of PCR tests, the false positives and the false negatives; the Great Barrington Declaration, which he considers not comprehensive enough; and the WHO Solidarity clinical trial, which shows the tested medications have little or no usefulness in hospital settings – a finding he insists has no relevance for outpatient treatment. (flu phase of the disease)
Professor Risch insists that even FDA’s own guidelines don’t require randomized control trials for Emergency Use Approval and that the available evidence, from an efficacy and safety perspective, is sufficient to grant such authorization to the drugs needed for early treatment. He also insists that there is no ground for any black box warning.
Moreover, he dismisses the argument according to which there could be shortages of the generic drugs used for early COVID-19, given the vast production capacity for those medications world-wide.
As in previous articles in academic journals such as the American Journal of Epidemiology and media such as Newsweek Washington Examiner, Professor Risch comments on the devastating implications of the misguided official policies regarding early treatment.
He maintains that the refusal by the US authorities to recommend the outpatient treatment of COVID-19, and the many restrictions to such early treatment that were implemented, have cost numerous lives over the past months, and will continue to unnecessarily cost many lives.
Finally, he comments on the progressive endemicity of COVID-19 in the USA and its health policy implications. For him, it’s not a matter of if, but when, people will get infected, and it’s a matter of adapting policies to this reality.
Watch this second part of the interview, and if you haven’t done so yet, also watch the first part – at the link below.